On January 3, 2023 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, reported that members of its senior management team will present and participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 4:30 pm Pacific Time (Press release, Lyell Immunopharma, JAN 3, 2023, View Source [SID1234625737]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the conference, Lyell executives will highlight the company’s growing pipeline of product candidates targeting solid tumors and T-cell reprogramming technologies, including its:
Lead CAR T cell and TIL product candidates, LYL797 and LYL845, which are in Phase 1 clinical development;
Second-generation ROR1 targeting CAR T-cell product candidate, LYL119, that incorporates two new reprogramming technologies
Newest stackable genetic and epigenetic reprogramming technologies:
NR4A3 gene knockout, that is being incorporated along with c-Jun overexpression to enhance the functional activity of CAR T cells; and
Stim-RTM, a programmable cell-signaling platform that optimizes signaling parameters during T-cell activation in order to generate more potent CAR T cells
A live webcast of the presentation can be accessed through the Investors section of the Company’s website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days following the presentation date.